DE3587498D1 - Antioestrogentherapie fuer symptome von oestrogenmangel. - Google Patents

Antioestrogentherapie fuer symptome von oestrogenmangel.

Info

Publication number
DE3587498D1
DE3587498D1 DE8585307298T DE3587498T DE3587498D1 DE 3587498 D1 DE3587498 D1 DE 3587498D1 DE 8585307298 T DE8585307298 T DE 8585307298T DE 3587498 T DE3587498 T DE 3587498T DE 3587498 D1 DE3587498 D1 DE 3587498D1
Authority
DE
Germany
Prior art keywords
estrogen
therapy
antioestrogen
oestrogen
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585307298T
Other languages
English (en)
Inventor
Ronald L Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BCM TECHN Inc
Original Assignee
BCM TECHN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BCM TECHN Inc filed Critical BCM TECHN Inc
Application granted granted Critical
Publication of DE3587498D1 publication Critical patent/DE3587498D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
DE8585307298T 1984-10-12 1985-10-11 Antioestrogentherapie fuer symptome von oestrogenmangel. Expired - Lifetime DE3587498D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/660,510 US4729999A (en) 1984-10-12 1984-10-12 Antiestrogen therapy for symptoms of estrogen deficiency

Publications (1)

Publication Number Publication Date
DE3587498D1 true DE3587498D1 (de) 1993-09-09

Family

ID=24649823

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585307298T Expired - Lifetime DE3587498D1 (de) 1984-10-12 1985-10-11 Antioestrogentherapie fuer symptome von oestrogenmangel.

Country Status (5)

Country Link
US (2) US4729999A (de)
EP (1) EP0178862B1 (de)
JP (1) JPH0680017B2 (de)
AT (1) ATE92314T1 (de)
DE (1) DE3587498D1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
US5516790A (en) * 1989-01-23 1996-05-14 Texas A&M University System Technology Licensing Office Synthesis and application of alkyl-substituted dibenzofurans as antitumorigenic agents
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) * 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) * 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
IL107343A (en) * 1992-11-02 2003-10-31 Wyeth Corp PHARMACEUTICAL COMPOSITION FOR LOWERING BLOOD LIPID LEVEL, COMPRISING, 17alpha-DIHYDROEQUILENIN
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
CA2152163A1 (en) * 1992-12-29 1994-07-07 Michael F. Holick Use of vitamin d glycosides for the treatment or prevention of osteoporosis
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
CZ285522B6 (cs) * 1993-06-24 1999-08-11 Eli Lilly And Company Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
US5681873A (en) * 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5637598A (en) * 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
CA2206422A1 (en) * 1994-11-29 1996-06-06 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
US5691384A (en) * 1994-11-29 1997-11-25 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
AU712711B2 (en) * 1994-11-29 1999-11-11 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
US5489587A (en) * 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
EP0722727A1 (de) * 1995-01-20 1996-07-24 Eli Lilly And Company Benzofuran-Derivate zur Hemmung der uterinem Fibrose
US5554600A (en) * 1995-01-20 1996-09-10 Eli Lilly And Company Methods for inhibiting endometriosis
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5747059A (en) * 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
JP2000506505A (ja) * 1996-01-11 2000-05-30 ノボ ノルディスク アクティーゼルスカブ 閉経期の症状の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
KR19980049229A (ko) * 1996-12-19 1998-09-15 이대원 줌렌즈 광학계
WO1998033499A1 (en) * 1997-01-29 1998-08-06 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women
WO1998034608A1 (en) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methods for treatment or prophylaxis of menopausal symptoms
US5789443A (en) * 1997-04-25 1998-08-04 Gollobin; Charlotte Method for treating flushing associated with menopause
WO1998048806A1 (en) * 1997-04-25 1998-11-05 Eli Lilly And Company Indene compounds having activity as serms
KR100440100B1 (ko) * 1997-07-25 2004-09-30 삼성테크윈 주식회사 리어 포커스식 소형 줌렌즈
HUP0002852A3 (en) 1997-08-15 2001-11-28 Univ Durham A method of preventing or treating estrogen-dependent diseases and disorders using triphenil-ethylene derivatives
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US6187329B1 (en) 1997-12-23 2001-02-13 Board Of Regents Of The University Of Texas System Variable permeability bone implants, methods for their preparation and use
US6255359B1 (en) 1997-12-23 2001-07-03 Board Of Regents Of The University Of Texas System Permeable compositions and methods for their preparation
US6733767B2 (en) * 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
ES2203131T3 (es) * 1998-05-15 2004-04-01 Wyeth 2-fenil-1-(-(2-aminoetoxi) bencilindol en combinacion con estrogenos.
WO1999066915A2 (en) * 1998-06-23 1999-12-29 Southern Illinois University At Carbondale Therapeutic applications of estrogenic carboxylic acids
US6323190B1 (en) 1998-07-31 2001-11-27 The Univeristy Of Georgia Research Foundation, Inc. Estrogen mimetics lacking reproductive tract effects
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
US6245812B1 (en) 1999-07-15 2001-06-12 Charlotte Gollobin Treatment of hot flashes (flushing) using leucine alone or in combination with other branched chain amino acids
JP2003513908A (ja) * 1999-08-31 2003-04-15 イエナファルム ゲゼルシャフト ミット ベシュレクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ホルモン補充療法（ｈｒｔ）のための組成物の成分としてのメソプロゲスチン（プロゲステロン受容体モジュレーター）
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
BR0111141A (pt) * 2000-05-26 2003-04-08 Harry Fisch Métodos de tratar a deficiência de androgênio em homens e de tratar distúrbios relacionados com menopausa masculina nos homens
US6326366B1 (en) 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
CN1289075C (zh) * 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
PT1666033E (pt) * 2001-11-29 2009-02-09 Gtx Inc Prevenção e tratamento de osteoporose induzida pela falta de androgénio
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
JP4481660B2 (ja) * 2002-04-02 2010-06-16 中外製薬株式会社 エストロン誘導体およびその製造方法
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
MX2007000050A (es) * 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
NZ556499A (en) * 2005-02-04 2011-02-25 Repros Therapeutics Inc Methods and materials with trans-clomiphene for the treatment of male infertility
BRPI0609389A2 (pt) * 2005-03-22 2010-03-30 Repros Therapeutics Inc tablete, composição e respectivos usos
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
AU2007252991B2 (en) * 2006-05-22 2012-08-02 Hormos Medical Ltd. Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
WO2007143607A2 (en) * 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
EP2518039B8 (de) * 2007-02-14 2014-12-17 Forendo Pharma Ltd. Verfahren zur Herstellung von therapeutisch nützlichen Triphenylbutenderivaten
ES2718912T3 (es) * 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales
CN101945853B (zh) 2007-12-21 2014-08-20 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
US20110301159A1 (en) * 2008-12-09 2011-12-08 University Of South Florida Kinase inhibitor compounds
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013117760A1 (en) 2012-02-10 2013-08-15 University College Cork, National University Of Ireland, Cork Light emitting diode chip
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
JP2015535283A (ja) 2012-11-02 2015-12-10 レプロス セラピューティクス インコーポレイティド 癌療法における使用のためのトランス−クロミフェン
WO2015108988A2 (en) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
CA2950390C (en) 2014-05-30 2020-09-22 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
ES2828305T3 (es) 2014-07-24 2021-05-26 Aspen Park Pharmaceuticals Inc Tratamiento de sofocos y pérdida ósea inducidos por tratamiento de privación de andrógenos utilizando cis-clomifeno
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US2914564A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of 1, 1, 2-triphenylethane
US2914562A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
US3634517A (en) * 1968-08-19 1972-01-11 Richardson Merrell Inc Triarylalkenones
US3697581A (en) * 1970-05-18 1972-10-10 American Home Prod 5-cycloalkylidene dibenzocycloheptene derivatives
US3843727A (en) * 1970-05-18 1974-10-22 American Home Prod 2-(cycloalkylidene-10,11-dihydro-5h-dibenzo(a,d)cycloheptene-2-yloxy)alkylene amines
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
IT1149935B (it) * 1980-07-02 1986-12-10 Finchimica Srl Uso farmacologico del 6-cloro-17-idrossi 1 alfa,2 alfa-metilpregna 4,6-dien-3,20-dione
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female

Also Published As

Publication number Publication date
US4894373A (en) 1990-01-16
US4729999A (en) 1988-03-08
JPH0680017B2 (ja) 1994-10-12
ATE92314T1 (de) 1993-08-15
JPS61178917A (ja) 1986-08-11
EP0178862A3 (en) 1988-09-28
EP0178862A2 (de) 1986-04-23
EP0178862B1 (de) 1993-08-04

Similar Documents

Publication Publication Date Title
DE3587498D1 (de) Antioestrogentherapie fuer symptome von oestrogenmangel.
EP0151989A3 (en) Means for the treatment of cardiac diseases
DE3583849D1 (de) Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ATE78169T1 (de) Behandlung von diabetes durch kombinierte insulinformen.
IL81573A (en) Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
HU907959D0 (en) Medical preparations
IE871567L (en) Method for treating depression
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
CZ28395A3 (en) Therapeutic composition containing whey protein concentrate
ES8706027A1 (es) Procedimiento de obtencion de una composicion para el tratamiento de vitiligo
FI93843B (fi) Menetelmä angiogeenisen tekijän tuottamiseksi
EG17992A (en) Preparation of a medicament for arthritis and theumatism
DK131586A (da) Transdermalt, antiallergisk, farmaceutisk praeparat
ATE207359T1 (de) Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin
Lendrum Surgical treatment of lichen planus of the soles
ATE66375T1 (de) Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
ATE65027T1 (de) Behandlung von parasiterkrankungen.
AP8500009A0 (en) New phenoxypropanolamine salts and pharmaceutical preparations thereof.
MXPA94000108A (es) Terapia transdermal de reemplazo de hormonas.
Teufel et al. Inhalt, Vol. 8, No. 6 1985
RO92915B1 (ro) Unguent cu actiune epitelizanta

Legal Events

Date Code Title Description
8364 No opposition during term of opposition